Short communication: Low positive anti-HCV microparticle enzyme immunoassay results: Do they predict hepatitis C virus infection?;Kisa bιldιrι: Mikropartikül enzim immunoassay ile düşük titrede saptanan anti-HCV pozitifliǧi hepatit C virus enfeksiyonunun tanιsιnda kullanιlabilir mi?

Mikrobiyoloji Bulteni

Volumn 40, Issue 1-2, 2006, Pages 81-84

  Sayan, Murat ^a   Meriç, Meliha ^a   Mutlu, Birsen ^a   Çelebi, Suna ^a   Willke, Ayşe ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Anti HCV; HCV RNA; Hepatitis C virus; Microparticle enzyme immunoassay; PCR

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ARTICLE; BLOOD; ENZYME IMMUNOASSAY; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; PREVALENCE; REPRODUCIBILITY; RETROSPECTIVE STUDY; STANDARD;

HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOENZYME TECHNIQUES; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 39049190005     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Centers for Disease Control and Prevention. Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991; 40 (RR4): 1-17.
2. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus (anti-HCV). MMWR 2003; 52 (RR3): 1-13.
3. Hyams KC, Riddle J, Rubertone M, et al. Prevalence and incidence of hepatitis C virus infection in the US military: a seroepiderniologic survey of 21,000 troops. Am J Epidemiol 2001;153: 764-70.
4. Moyer LA, Mast EE, Alter MJ. Hepatitis C: Part I. Routine serologic testing and diagnosis. Am Fam Phys 1999; 59: 1-12.
5. Oethinger M, Mayo DR, Falcone JA, Barua PK, Griffith BP. Efficiency of the ortho VITROS assay for detection of hepatitis C virus-specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios. J Clin Microbiol 200; 43: 2477-80.
6. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Recommendations and Reports. MMWR 2003; 52(RR03): 1-16.
7. Pawlotsky JM, Lonjon I, Hezode C, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-2.
8. Lok AS, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997; 26: 48-56.
9. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury: I. Characteristics of laboratory tests. Clin Chem 2000; 46: 2027-49.
10. Dufour DR, Talastas M, Fernandez MDA, Harris B, Strader DB, Seeff LB. Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem 2003; 49: 479-86.
11. Bossi V, Galli C. Quantitative signal of anti-HCV by an automated assay predicts viremia in a population at high prevalence of hepatitis C virus infection. J Clin Virol 2004; 30: 45-9.
12. MacKenzie WR, Davis JP, Peterson DE, Hibbard AJ, Becker G, Zarvan BS. Multiple false-positive serologic tests for HIV, HTLV-1, and hepatitis C following influenza vaccine, 1991. JAMA 1992; 268: 1015-7.
13. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971-1975. Hepatology 2000; 32: 582-7.
14. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B hepatitis and type C hepatitis: a national heart, lung, and blood institute collaborative study. Hepatology 2001; 33: 455-63.